Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD is a China-based pharmaceutical company primarily engaged in the research, development, production, and sales of Chinese patent medicines, health food products, and active pharmaceutical ingredients (APIs). The company offers a broad product portfolio including Chinese proprietary medicines such as Lung Relief Tonic, Yuanhu Pain Relief Drops, Jujube Kernel Oil Drops, Berberine Tannic Acid Membranes, Shichiwei Wenyang Capsules, Apricot Cough Relief Capsules, Compound Salvia Tablets, Sanqian Medicine Tablets, Anti-inflammatory Cholesterol Tablets, Astragalus Angelica Capsules, Conjugation Tablets, and various pediatric formulations such as Pediatric Lung Clearing Tablets and Pediatric Cough Cleanse Tablets. Additionally, it manufactures chemical pharmaceutical preparations and intermediates, and related health care products. The company operates mainly in China and holds multiple certifications and honors including provincial technology center status, famous brand recognition, and awards for innovation and quality. Founded in 2002 and headquartered in Gansu, China, it is listed on the Shenzhen Stock Exchange (Ticker: 300534.SZ) and controlled by Gansu Pharmaceutical Investment Group Co., Ltd. Recent major company developments include the strategic acquisitions of Gansu Puan Pharmaceutical Co., Ltd in 2023 and Gansu Pharmaceutical Group Science and Technology Innovation Research Institute Co., Ltd in 2025. These acquisitions have strengthened its capital base and enhanced its market competitiveness and profitability. Its holding subsidiary has also obtained a renewed drug manufacturing license, reflecting continuous regulatory compliance and operational capability. The company focuses on integrating capital and assets to drive growth while expanding its R&D capabilities and product offerings in the pharmaceutical and health food sectors.